High triglycerides
A high level of triglycerides, a type of fat, in the blood. A high level can raise the risk of heart diseases such as coronary artery disease, and extremely high levels also raise the risk of acute pancreatitis.
Also called High triglycerides · Hypertriglyceridemia
- Condition
- In this atlas
Overview
Technical summary
MeSH descriptor D015228. MedlinePlus has a health topic and a medical test page on triglycerides. Its parent here is dyslipidemia. The evidence recorded here is descriptive; the level categories on the MedlinePlus page are not repeated.
Burden
No burden claims are published.
Claims and evidence
Context People with high cholesterol or high triglycerides (MedlinePlus patient pages and MeSH)
- Recipient
- Mixed recipients
- Population
- People with abnormal blood fat levels, such as high cholesterol or high triglycerides, as described by MedlinePlus patient pages and MeSH. MedlinePlus says younger people, including children and teens, can also have high cholesterol.
- Care setting
- Not stated; patient information pages and a vocabulary
- Geography
- Not stated; United States federal health agencies
- Life stage
- All ages; the cholesterol page says children and teens can also have high cholesterol
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (descriptive page)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
- Included
- None stated
- Excluded
- None stated
MeSH describes hypertriglyceridemia as a condition of elevated levels of triglycerides in the blood. MedlinePlus says a high level of triglycerides can raise the risk of heart diseases such as coronary artery disease, and that high levels may affect the arteries and raise the risk of coronary artery disease, heart attack and blood vessel disorders. It adds that extremely high levels also increase the risk of acute pancreatitis in adults and children.
Applies to Mixed recipients People with high cholesterol or high triglycerides (MedlinePlus patient pages and MeSH)
- Certainty method
- Not assessed
- Limitations
- MeSH is a vocabulary and its scope note sets no threshold. A patient-information or vocabulary source: it describes the condition and the direction of any risk. It gives no size for the risk, no time frame and no comparison group, and it is not clinical advice.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
Supports MeSH scope note for descriptor D015228 (Hypertriglyceridemia)
- Locator
- scopeNote.@value
- How it applies
- MeSH scope note for the descriptor.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
42bb7aeeeae222436584a6f6b39c9f929f9a85d6a2188d05a87793de21799b51- Reuse basis
- The NLM web policies page (fetched 2026-10-30, sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. Source: National Library of Medicine. This copy was fetched on 2026-10-30 and may not reflect the most current data. The raw bytes are committed in the atlas repository.
-
Supports Triglycerides (MedlinePlus health topic)
- Locator
- Summary, What are triglycerides?, para 3
- How it applies
- MedlinePlus health topic on heart disease risk.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
b7cd13120948ff2eeeebcfe6fd34831554fe9cfe21875cc5da03fbe7d3adb110- Reuse basis
- MedlinePlus states that works produced by the federal government are not copyrighted, and lists summaries on health topic pages, medical test information and Genetics pages as public domain (the page titled Linking to and Using Content from MedlinePlus, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161, hash only). It names the A.D.A.M. encyclopedia, drug monographs and many images as copyrighted; this atlas uses only the page text. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
-
Supports Triglycerides Test (MedlinePlus medical test)
- Locator
- What is a triglycerides test?, para 3
- How it applies
- MedlinePlus medical test page on arteries and pancreatitis.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
fe517bdd7bf731cff61b427d43af3410eedc79c95175571ad07d67a2976a4d9d- Reuse basis
- MedlinePlus states that works produced by the federal government are not copyrighted, and lists summaries on health topic pages, medical test information and Genetics pages as public domain (the page titled Linking to and Using Content from MedlinePlus, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161, hash only). It names the A.D.A.M. encyclopedia, drug monographs and many images as copyrighted; this atlas uses only the page text. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact MedlinePlus: a high level of triglycerides can raise the risk of coronary artery disease: Coronary artery disease
Applies to Mixed recipients People with high cholesterol or high triglycerides (MedlinePlus patient pages and MeSH)
MeSH describes hypertriglyceridemia as a condition of elevated levels of triglycerides in the blood. MedlinePlus says a high level of triglycerides can raise the risk of heart diseases such as coronary artery disease, and that high levels may affect the arteries and raise the risk of coronary artery disease, heart attack and blood vessel disorders. It adds that extremely high levels also increase the risk of acute pancreatitis in adults and children.Limitations. MeSH is a vocabulary and its scope note sets no threshold. A patient-information or vocabulary source: it describes the condition and the direction of any risk. It gives no size for the risk, no time frame and no comparison group, and it is not clinical advice.
-
Claim, not a settled fact Evaluated for this: Fenofibrate
Applies to Adult Adults with severe hypertriglyceridemia or primary hyperlipidemia, as described in the US label of Antara fenofibrate capsules
Population, setting and follow-up
- Adults with severe hypertriglyceridemia, and adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible, as the indications section of the label states.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Adults, as the label states
The US label of Antara (fenofibrate capsules, Lupin Pharmaceuticals, Inc., application NDA021695; the version dated 2025-10-01 in openFDA) lists two uses as adjunctive therapy to diet in adults: reducing triglyceride levels in severe hypertriglyceridemia, and reducing elevated LDL cholesterol in primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. The label also says fenofibrate did not reduce coronary heart disease morbidity and mortality in two large randomized controlled trials of patients with type 2 diabetes mellitus. It calls the medicine a PPAR alpha agonist.Limitations. This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Fenofibrate products differ in form and in labelled uses; only the Antara capsule label was read. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Icosapent ethyl
Applies to Adult Adults with raised triglycerides, as the US Vascepa label describes them
Population, setting and follow-up
- Adult patients named in the indications of the US label for Vascepa: adults with elevated triglycerides and established cardiovascular disease or diabetes plus other risk factors, and adults with severe hypertriglyceridemia.
- Prescription medicine; the label adds the medicine to statin treatment or to diet, as stated in the indications
- United States (FDA label)
- Adults; the label states adult patients
The US Vascepa label says Vascepa (icosapent ethyl) is indicated, as an add-on to statin treatment at the highest dose the patient can tolerate, to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride levels (150 mg/dL or higher) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease. It is also indicated, as an adjunct to diet, to reduce triglyceride levels in adult patients with severe (500 mg/dL or higher) hypertriglyceridemia. The label says the effect on the risk of pancreatitis in patients with severe hypertriglyceridemia has not been determined.Limitations. These are indications as the label states them, in the label version dated 2026-03-23. They say what FDA has approved the medicine for, not how well it works for any person. The trial evidence behind the cardiovascular indication is not read in this atlas yet.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 58
Record details
- Record id
cardio:hypertriglyceridemia- Content hash
8d2ecf2e76144dff804a9c389fef88ef270b2c043e5f53ff9b16da41cbdbdc5e